NeuroVive Pharmaceutical ABのIPO年
NeuroVive Pharmaceutical ABのIPO年は何ですか。
NeuroVive Pharmaceutical ABのIPO年は2018です。
IPO年の定義は何ですか。
新規公開株 (IPO)は、企業の株式を通常は機関投資家に販売し、順番に証券取引所で一般市民に販売する株式公開の一種です。
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
OTCのセクタHealth CareにおけるIPO年の企業と比べるNeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical ABは何をしますか。
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
NeuroVive Pharmaceutical ABと類似のipo年
- Mediawan SAのIPO年は2017です。
- SouthernのIPO年は2017です。
- Polytec Hldg Ag Inh. Eo 1のIPO年は2017です。
- Roots Sustainable Agricultural TechnologiesのIPO年は2017です。
- Galena MiningのIPO年は2017です。
- MVC Capital IncのIPO年は2017です。
- NeuroVive Pharmaceutical ABのIPO年は2018です。
- Bermele plcのIPO年は2019です。
- Twin River WorldwideのIPO年は2019です。
- Contel TechnologyのIPO年は2019です。
- GraniteShares 3x Long Diageo Daily ETCのIPO年は2019です。
- Pinterest IncのIPO年は2019です。
- Ferrellgas Partners, L.PのIPO年は2019です。